Phase 2 Pulmonary Arterial Hypertension Clinical Trials
11 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–11 of 11 trials
Recruiting
Phase 2
Spironolactone for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
National Institutes of Health Clinical Center (CC)70 enrolled1 locationNCT01712620
Recruiting
Phase 1Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals232 enrolled85 locationsNCT06649110
Recruiting
Phase 2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC42 enrolled35 locationsNCT05587712
Recruiting
Phase 2
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
Pulmonary Arterial Hypertension
Apollo Therapeutics Ltd48 enrolled5 locationsNCT06846554
Recruiting
Phase 2
129 Xenon Imaging in Patients Treated With Sotatercept
Pulmonary HypertensionPulmonary Arterial Hypertension
Bastiaan Driehuys14 enrolled1 locationNCT06351345
Recruiting
Phase 2
Pulmonary Hypertension SOLAR
COPDInterstitial Lung DiseasePulmonary Arterial Hypertension
Bastiaan Driehuys30 enrolled1 locationNCT04778046
Recruiting
Phase 2
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial HypertensionConnective Tissue DiseasesIdiopathic Pulmonary Arterial Hypertension+1 more
Bastiaan Driehuys20 enrolled1 locationNCT06104228
Recruiting
Phase 2
Xenon MRI Pulm Hypertension
Pulmonary HypertensionPulmonary Arterial Hypertension
Bastiaan Driehuys60 enrolled1 locationNCT04991454
Recruiting
Phase 2
Repurposing Valsartan May Protect Against Pulmonary Hypertension
Pulmonary Arterial HypertensionRight Ventricular DysfunctionRight Heart Failure+1 more
University of Washington60 enrolled1 locationNCT06053580
Recruiting
Phase 2Phase 3
Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation260 enrolled1 locationNCT06683040
Terminated
Phase 2
To identify the effective dose(s) of RT234 (vardenafil inhalation powder) to acutely improve pulmonary vascular haemodynamics in study participants with Pulmonary Arterial Hypertension (PAH).
Pulmonary Arterial Hypertension
Respira Therapeutics Australia Pty Ltd15 enrolled3 locationsACTRN12619001178134